The scientist in society

Internationally known reproductive biologist S.K. Dey advocates “a million scientists march” on Washington to sound the alarm about regulatory impediments and dwindling research support that are slowing the pace of progress. If the situation doesn’t improve, he warns, scientists may become “an endangered species.”  read article

The people's agenda

Elizabeth Nabel, M.D., director of the National Heart, Lung, and Blood Institute, and Rose Marie Robertson, M.D., chief science officer of the American Heart Association and professor of Medicine at Vanderbilt, discuss how public-private partnerships can advance the fight against heart disease and stroke.  read article

Investing social capital

Haitian AIDS researcher Jean William Pape, M.D., and David Holtgrave, Ph.D., an expert on HIV prevention programs at the Johns Hopkins Bloomberg School of Public Health, share their views about what it takes to conduct AIDS research in resource-poor countries, and what the United States can learn from these experiences.  read article

Brave New Visions

Merck scientist Richard Hargreaves and neuroethicist Judy Illes discuss the challenges of imaging technology. Can imaging lower the cost of new drugs? Are there places we shouldn't go?  read article

Getting the drugs we need

Steven M. Paul, M.D., president of Lilly Research Laboratories, and Vanderbilt’s Alastair J.J. Wood, M.B., Ch.B., who chaired the recent FDA advisory panel on COX-2 inhibitors, tackle some of the economic and legal challenges facing the nation’s pharmaceutical industry. Among their suggestions: improved patent protection and other incentives to encourage the development of “the drugs that we need.”  read article

Teamwork + Trust

Sir Ravinder Maini, who helped discover a new class of anti-inflammatory drugs, discusses the limitations of clinical trials, the importance of post-marketing surveillance and the value of university-industry partnerships.  read article

Retroviruses, engineering and the future of science

Two of the nation’s most prominent Nobel laureates—David Baltimore and Harold Varmus—iscuss recent scientific advances, including the potential to “engineer” the immune system to prevent viral infections, as well as the changing roles of government and the private sector in advancing the research enterprise, and the need to improve the public’s “science literacy.”  read article

Cracking the brainís genetic code

Two of the nation's leading experts in neuropsychopharmacology—Drs. Joseph T. Coyle of Harvard Medical School and Edward M. Scolnick of the Broad Institute of MIT and Harvard—discuss the development of new medications to treat disorders of brain function. A major step forward has been the identification of "risk genes" that—in combination—may disturb normal brain development.  read article

Forging new partnerships

Allen Spiegel, M.D., is an internationally recognized endocrinologist whose research has helped define the genetic basis of several endocrine diseases. A former director of the National Institute of Diabetes and Digestive and Kidney Diseases, Spiegel currently is dean of the Albert Einstein College of Medicine of Yeshiva University.  read article

The future of proteomics

Two of the nation’s most prominent leaders in biotechnology, Tony White and Mike Hunkapiller, sit down with Lens for a wide-ranging interview on the challenges facing the field of proteomics, the growing need for collaboration between government, universities and private companies, and the potential impact that the debate over stem-cell research may have on scientific progress.  read article

A problem of social injustice

Harold Freeman, M.D., former president of the American Cancer Society, and Jane Weeks, M.D., chief of Population Sciences at the Dana-Farber Cancer Institute, discuss what needs to be done to reduce the disproportionate impact of cancer on racial and ethnic groups, the poor and the elderly.  read article